 Menlo Therapeutics Inc. Menlo MNLO, a specialty pharmaceutical company focused on developing and commercializing proprietary therapies to address unmet needs in dermatology, today announced that it intends to offer and sell, subject to market conditions, shares of its common stock in an underwritten public offering. All of the common stock to be sold in the offering will be offered by Menlo. In addition, Menlo expects to grant the underwriters a 30-day option to purchase up to an additional 15 of the shares of common stock offered in the public offering. 